AstraZeneca

200 articles with AstraZeneca

• AliveCor Announces Collaboration with AstraZeneca to Develop Non-Invasive Potassium Monitoring Solutions

  2/16/2021

  AliveCor, the leader in AI-based personal ECG technology and provider of enterprise cardiology solutions, today announced a new collaboration with AstraZeneca

• Matrix Medical Network Collaborates with AstraZeneca on Phase III Clinical Trial for COVID-19 Long-Acting Antibody Combination

  2/3/2021

  Matrix Medical Network Will Provide Mobile Health Clinics and Experienced Clinicians to Reach High Risk and Hard to Recruit Populations in AstraZeneca's Phase III STORM CHASER Prevention Trial in the US

• Statement on the European Medicines Agency's recommended authorization of the AstraZeneca COVID-19 vaccine

  1/29/2021

  Health Canada is aware that the European Medicines Agency has recommended granting a conditional marketing authorization for the COVID-19 vaccine manufactured by AstraZeneca and Oxford University.

• TAGRISSO Extended Disease-Free Survival Regardless of Prior Adjuvant Chemotherapy in Early-Stage EGFR-Mutated Lung Cancer

  1/29/2021

  TAGRISSO Extended Disease-Free Survival Regardless of Prior Adjuvant Chemotherapy in Early-Stage EGFR-Mutated Lung Cancer Data at WCLC showed patients in the practice-changing ADAURA Phase III trial maintained their quality of life based on patient-reported outcomes New data reinforce the ability of TAGRISSO to penetrate the blood-brain barrier in patients with central nervous system metastases

• CALQUENCE Met Primary Efficacy Endpoint in Head-to-Head Trial Against ibrutinib in Chronic Lymphocytic Leukemia

  1/25/2021

  Positive high-level results from the ELEVATE-RR Phase III trial showed AstraZeneca’s CALQUENCE ® (acalabrutinib) met the primary endpoint demonstrating non-inferior progression-free survival (PFS) for adults with previously treated, high-risk chronic lymphocytic leukemia (CLL) compared to ibrutinib. The trial also met a key secondary endpoin

• ENHERTU® (fam-trastuzumab deruxtecan-nxki) Approved in the US for the Treatment of Patients with Previously Treated HER2-Positive Advanced Gastric Cancer

  1/18/2021

  AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.

• AstraZeneca to Showcase Transformative Data Across Diverse Pipeline at World Conference on Lung Cancer

  1/13/2021

  AstraZeneca will present new data from across the innovative lung cancer portfolio at the IASLC 2020 World Conference on Lung Cancer (WCLC), hosted by the International Association for the Study of Lung Cancer, 28 to 31 January 2021.

• GRAIL Announces Collaborations with Amgen, AstraZeneca, and Bristol Myers Squibb to Evaluate Cancer Early Detection Technology for Minimal Residual Disease

  1/11/2021

  GRAIL, Inc., a healthcare company whose mission is to detect cancer early, today announced collaborations with global biopharmaceutical companies Amgen (NASDAQ:AMGN), AstraZeneca (LSE/STO/Nasdaq: AZN), and Bristol Myers Squibb (NYSE: BMY) to evaluate GRAIL’s methylation-based technology for the detection of minimal residual disease (MRD). Cancer MRD testing is used in clinical and research applications to detect

• Ultimovacs Announces Phase II DOVACC Collaboration Study in Ovarian Cancer With the Nordic Society of Gynaecological Oncology – Clinical Trial Unit, the European Network of Gynaecological Oncological Trial Groups and AstraZeneca

  1/11/2021

  Ultimovacs ASA, announced its participation in the Phase II DOVACC collaboration study with the Nordic Society of Gynaecological Oncology – Clinical Trial Unit, the European Network of Gynaecological Oncological Trial Groups and AstraZeneca, to conduct a randomized Phase II clinical trial to evaluate Ultimovacs’ proprietary universal cancer vaccine, UV1, in combination with AstraZeneca’s durvalumab and olaparib in patients with relapsed ovarian cancer.

• Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of Novel Diagnostics and Therapeutics

  1/11/2021

  Multi-year, pan-portfolio deal extends Adaptive’s proprietary immunoSEQ T-MAP offering, originally launched for COVID-19, into oncology This transaction highlights the value of immune receptor data generated by Adaptive’s proprietary immune medicine platform

• LYNPARZA® (olaparib) Receives Three New Approvals in Japan

  12/28/2020

  LYNPARZA ® (olaparib) Receives Three New Approvals in Japan Approvals in Three Types of Cancer Are Based on the PAOLA-1, PROfound and POLO Phase 3 Trials

• ADDING MULTIMEDIA TAGRISSO Approved in the US for the Adjuvant Treatment of Patients With Early-Stage EGFR-mutated Lung Cancer

  12/21/2020

  Approval based on unprecedented results from the ADAURA Phase III trial where TAGRISSO reduced the risk of disease recurrence or death by 80%

• AstraZeneca Demonstrates Growing Leadership in Breast Cancer at SABCS with Data From Its Innovative Medicines and Robust Pipeline

  12/3/2020

  New data from the DESTINY-Breast01 trial reinforce the efficacy of ENHERTU ® in HER2-positive metastatic breast cancer New data from the SERENA-1 Phase I trial show strong efficacy and safety profile for next-generation oral SERD AZD9833 in HR-positive advanced breast cancer

• AstraZeneca France Using Questionmark Online Assessments to Train On-Field Sales Teams

  11/24/2020

  The French subsidiary of AstraZeneca, the leading global pharmaceutical company, is assessing the scientific knowledge of its on-field sales team using Questionmark’s enterprise-grade assessment platform . Ensuring those teams are up to date on the latest science is a priority for the bu

• Ionis announces third investigational antisense medicine to treat nonalcoholic steatohepatitis (NASH) enters development

  11/23/2020

  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that the biopharmaceutical company AstraZeneca has licensed ION455, an investigational antisense medicine being developed as a potential treatment for nonalcoholic steatohepatitis (NASH)

• IMFINZI® (durvalumab) Approved In The US For Less-Frequent, Fixed-Dose Use

  11/20/2020

  AstraZeneca’s IMFINZI® (durvalumab) has been approved in the US for an additional dosing option, a 1,500mg fixed dose every four weeks, in the approved indications of unresectable Stage III non-small cell lung cancer (NSCLC) after chemoradiation therapy (CRT) and previously treated advanced bladder cancer.

• AstraZeneca demonstrates strengths in haematology with robust data at ASH 2020

  11/19/2020

  AstraZeneca will present new research aimed at addressing key unmet needs facing patients with blood cancers at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, held virtually from 5 to 8 December 2020.

• AstraZeneca Demonstrates Strength in Hematology With Robust Data at ASH 2020

  11/19/2020

  AstraZeneca Demonstrates Strength in Hematology With Robust Data at ASH 2020 Presentations support CALQUENCE efficacy and tolerability with long-term follow-up in mantle cell lymphoma and pooled safety data in chronic lymphocytic leukemia Emerging pipeline shows promise in novel targets and mechanisms to treat resistant and aggressive blood cancers

• Data from contemporary registry confirms that four out of five patients with heart failure with reduced ejection fraction eligible for treatment with FARXIGA

  11/13/2020

  TRANSLATE-HF study establishes the potential for broad use of the only SGLT2 inhibitor indicated in patients with heart failure with reduced ejection fraction with and without diabetes

• AstraZeneca Partners with CCT to Conduct COVID-19 Vaccine Clinical Trials in Arizona

  11/12/2020

  CCT Research  (CCT), a leader in community-based, embedded clinical research, today announced its partnership with AstraZeneca to advance COVID-19 research. Together with local healthcare providers, CCT will facilitate clinical trials for the AZD1222 C